XML 46 R46.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue Recognition - Additional Information (Detail)
¥ in Billions
1 Months Ended 3 Months Ended
May 17, 2018
USD ($)
item
Apr. 30, 2013
USD ($)
item
Apr. 30, 2012
USD ($)
Mar. 31, 2020
USD ($)
item
Milestone
Mar. 31, 2019
USD ($)
Milestone
Dec. 31, 2019
USD ($)
Apr. 30, 2013
JPY (¥)
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Deferred revenue, current       $ 14,241,000   $ 22,262,000  
Deferred revenue, non current       0      
Total revenue       $ 8,093,000 $ 4,382,000    
Number of milestone event probable of occurrence or achieved | Milestone       0 0    
License and Milestone Fees [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Total revenue       $ 8,021,000 $ 4,242,000    
Royalty [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue from contract with customer       0      
VFMCRP Agreement [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Deferred revenue, current       14,241,000   22,262,000  
Receivables       0      
Other assets           0  
Deferred revenue $ 55,444,000            
Number of combined performance obligations for revenue recognized | item 1            
Number of performance obligations for revenue recognized | item 2            
upfront payment $ 50,000,000            
Premium from sale of stock $ 5,444,000            
Remaining performance obligations       $ 14,241,000      
Remaining performance obligation, expected timing of satisfaction, year       2020      
VFMCRP Agreement [Member] | License and Milestone Fees [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Total revenue       $ 8,021,000      
License and milestone fees recognized       41,203,000      
Maruishi and CKDP Agreements [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Receivables       $ 0      
Other assets           0  
Deferred revenue           $ 0  
Number of remaining performance obligations | item       0      
Maruishi Agreement [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Number of performance obligations for revenue recognized | item   2          
Premium from sale of stock   $ 337,000          
Upfront non-refundable, non-creditable license fee and premium from sale of stock   15,337,000          
Maruishi Agreement [Member] | Clinical Development and Regulatory Milestones [Member] | Maximum [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Remaining potential consideration   10,500,000          
Maruishi Agreement [Member] | One-time Sales Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Remaining potential consideration | ¥             ¥ 1
Maruishi Agreement [Member] | License [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Estimated selling price   10,200,000          
Upfront payments on obligations   9,637,000          
Maruishi Agreement [Member] | R&D Services [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Estimated selling price   6,200,000          
Upfront payments on obligations   $ 5,700,000          
CKDP Agreement [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Premium from sale of stock     $ 83,000        
CKDP Agreement [Member] | Clinical Development and Regulatory Milestones [Member] | Maximum [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Remaining potential consideration     3,750,000        
CKDP Agreement [Member] | License [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue from contract with customer     $ 646,000